tesmilifene has been researched along with Benign Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista, AA; Cominetti, MR; Correa, RS; de Oliveira, KM; Ellena, J; Godoy, LR; Graminha, AE; Honorato de Araujo-Neto, J; Popolin, C; Vegas, LC | 1 |
| Bracken, SP; Brandes, LJ; Simons, KJ; Warrington, RC | 1 |
1 trial(s) available for tesmilifene and Benign Neoplasms
| Article | Year |
|---|---|
Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Histamine Antagonists; Humans; Male; Middle Aged; Neoplasms; Phenyl Ethers; Tumor Cells, Cultured | 1994 |
1 other study(ies) available for tesmilifene and Benign Neoplasms
| Article | Year |
|---|---|
New ruthenium complexes containing salicylic acid and derivatives induce triple-negative tumor cell death via the intrinsic apoptotic pathway.
Topics: Aminosalicylic Acid; Amobarbital; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coordination Complexes; Humans; Neoplasms; Phosphorus; Ruthenium; Salicylic Acid | 2022 |